Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCLG-APL 2024 pediatric APL protocol
ChiCTR2400085721Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax, tretinoin and arsenic in Acute promyelocytic leukaemia (APL), sponsored by Beijing Children's Hospital. Primary endpoints: Overall survival and Event-free survival. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
venetoclaxtretinoinarsenic
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR2400085721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085721.